These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 35123664

  • 1. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P, Orsini F, Lozinsky AC, Gold M, O'Sullivan MD, Quinn P, Lloyd M, Ashley SE, Pitkin S, Axelrad C, Metcalfe JR, Su EL, Tey D, Robinson MN, Allen KJ, Prescott SL, Galvin AD, Tang MLK, PPOIT-003 study group.
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [Abstract] [Full Text] [Related]

  • 2. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
    Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, Licciardi P, Burks W, Donath S.
    J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
    [Abstract] [Full Text] [Related]

  • 3. Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study).
    Chebar Lozinsky A, Loke P, Orsini F, O'Sullivan M, L Prescott S, Gold MS, Quinn P, DunnGalvin A, Lk Tang M, PPOIT study team.
    BMJ Open; 2020 Sep 09; 10(9):e035871. PubMed ID: 32912942
    [Abstract] [Full Text] [Related]

  • 4. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A.
    Cochrane Database Syst Rev; 2012 Sep 12; 2012(9):CD009014. PubMed ID: 22972130
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS, Purington N, Andorf S, Long A, O'Laughlin KL, Lyu SC, Manohar M, Boyd SD, Tibshirani R, Maecker H, Plaut M, Mukai K, Tsai M, Desai M, Galli SJ, Nadeau KC.
    Lancet; 2019 Oct 19; 394(10207):1437-1449. PubMed ID: 31522849
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, Scurlock AM, Chinthrajah S, Wang J, Pesek RD, Sindher SB, Kulis M, Johnson J, Spain K, Babineau DC, Chin H, Laurienzo-Panza J, Yan R, Larson D, Qin T, Whitehouse D, Sever ML, Sanda S, Plaut M, Wheatley LM, Burks AW, Immune Tolerance Network.
    Lancet; 2022 Jan 22; 399(10322):359-371. PubMed ID: 35065784
    [Abstract] [Full Text] [Related]

  • 8. Study protocol of a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study).
    Loke P, Chebar Lozinsky A, Orsini F, Wong LS, Leung AS, Tham EH, Lopata AL, Shek LP, Tang ML, PEAT study team.
    BMJ Open; 2021 Jul 07; 11(7):e044331. PubMed ID: 34233966
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy.
    Blumchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G, Heinzmann A, Nemat K, Holzhauser T, Roeder M, Rosenfeld L, Hartmann O, Niggemann B, Beyer K.
    J Allergy Clin Immunol Pract; 2019 Feb 07; 7(2):479-491.e10. PubMed ID: 30423449
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
    Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, Wood RA.
    J Allergy Clin Immunol; 2015 May 07; 135(5):1275-82.e1-6. PubMed ID: 25528358
    [Abstract] [Full Text] [Related]

  • 14. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial.
    Hsiao KC, Ponsonby AL, Axelrad C, Pitkin S, Tang MLK, PPOIT Study Team.
    Lancet Child Adolesc Health; 2017 Oct 07; 1(2):97-105. PubMed ID: 30169215
    [Abstract] [Full Text] [Related]

  • 15. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
    Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW.
    J Allergy Clin Immunol; 2014 Feb 07; 133(2):468-75. PubMed ID: 24361082
    [Abstract] [Full Text] [Related]

  • 16. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial: a critical appraisal.
    Marrs T, Flohr C, Perkin MR.
    Br J Dermatol; 2015 Nov 07; 173(5):1125-9. PubMed ID: 26769642
    [Abstract] [Full Text] [Related]

  • 17. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
    Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, Keet CA, Kulis M, Orgel KG, Guo R, Steele PH, Virkud YV, Ye P, Wright BL, Wood RA, Burks AW.
    J Allergy Clin Immunol; 2017 Jan 07; 139(1):173-181.e8. PubMed ID: 27522159
    [Abstract] [Full Text] [Related]

  • 18. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
    Nagakura KI, Yanagida N, Sato S, Nishino M, Asaumi T, Ogura K, Ebisawa M.
    Pediatr Allergy Immunol; 2018 Aug 07; 29(5):512-518. PubMed ID: 29603410
    [Abstract] [Full Text] [Related]

  • 19. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K, Burk C, Smeekens J, Suber J, Hardy L, Guo R, Burks AW, Kulis M.
    Clin Exp Allergy; 2019 Apr 07; 49(4):461-470. PubMed ID: 30383313
    [Abstract] [Full Text] [Related]

  • 20. Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy.
    Nagakura KI, Sato S, Yanagida N, Nishino M, Asaumi T, Ogura K, Ebisawa M.
    Int Arch Allergy Immunol; 2018 Apr 07; 175(3):181-188. PubMed ID: 29339650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.